Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 234,875,032 papers from all fields of science
Search
Sign In
Create Free Account
MPDL3280A
Known as:
MPDL-3280A
, MPDL328OA
, MPDL 328OA
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
atezolizumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Diagnostic and therapeutic methods for cancer
皮提 赫格德
,
馬路克 胡賽尼
2018
Corpus ID: 208467176
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g.,kidney…
Expand
2016
2016
Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
S. Adams
,
J. Diamond
,
+8 authors
J. Powderly
2016
Corpus ID: 75902809
Background: Metastatic triple-negative breast cancer (mTNBC) is associated with poor prognosis, and chemotherapy remains the…
Expand
2016
2016
Abstract OT1-01-06: A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
L. Emens
,
S. Adams
,
+5 authors
E. Winer
2016
Corpus ID: 76793414
Background: The management of mTNBC is a therapeutic challenge, and chemotherapy remains the mainstay of treatment. Atezolizumab…
Expand
2015
2015
Bladder cancer: Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?
Annette Fenner
Nature reviews. Urology
2015
Corpus ID: 27366170
Bladder cancer: Could MPDL3280A offer a therapeutic breakthrough in metastatic bladder cancer?
2015
2015
MPDL3280A Shows Activity in Triple-Negative Breast Cancer
A. Azvolinsky
2015
Corpus ID: 145959430
In an ongoing study, the immunotherapy MPDL3280A continues to be well-tolerated and to show signs of activity in triple-negative…
Expand
2015
2015
Title The prognostic significance of PD-L 1 in bladder cancer
Yide Huang
,
Shu-Dong Zhang
,
C. McCrudden
,
K. Chan
,
Yao Lin
,
H. Kwok
2015
Corpus ID: 174796460
Immunotherapy is a promising strategy for the treatment of various types of cancer. An antibody that targets programmed death…
Expand
2015
2015
Human Vaccines and Immunotherapeutics: News
Human Vaccines & Immunotherapeutics
2015
Corpus ID: 30381479
Checkpoint inhibitors promising in lung, liver, head and neck and skin cancers Two PD-1 inhibitors were successful in non-small…
Expand
2014
2014
Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer (UBC)
Yuanyuan Xiao
,
C. Rabe
,
+14 authors
P. Hegde
2014
Corpus ID: 91110686
2014
2014
PD-L1 Inhibitor MPDL3280A Promising for Smokers with Refractory NSCLC
P. Goodwin
2014
Corpus ID: 137875256
2013
2013
Anti-PD-L1 Antibody MPDL3280A Active in Metastatic Melanoma
A. Azvolinsky
2013
Corpus ID: 182515483
About one-third of patients with advanced cutaneous melanoma treated with MPDL3280A, an antibody against the programmed death 1…
Expand